All Stories

  1. An oncolytic HSV-1 vector induces a therapeutic adaptive immune response against glioblastoma

    Article • Journal of Translational Medicine, September 2024, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  2. A Truncated Isoform of Cyclin T1 Could Contribute to the Non-Permissive HIV-1 Phenotype of U937 Promonocytic Cells

    Article • Viruses, July 2024, MDPI AG

    MD, PhD Roberto S Accolla

  3. Novel vaccination strategies based on optimal stimulation of CD4+ T helper cells for the treatment of oral squamous cell carcinoma

    Article • Frontiers in Immunology, July 2024, Frontiers

    MD, PhD Roberto S Accolla

  4. The NLR member CIITA: Master controller of adaptive and intrinsic immunity and unexpected tool in cancer immunotherapy

    Article • Biomedical Journal, October 2023, Elsevier

    MD, PhD Roberto S Accolla

  5. Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly

    Article • International Journal of Molecular Sciences, September 2023, MDPI AG

    MD, PhD Roberto S Accolla

  6. Protective anti-tumor vaccination against glioblastoma expressing the MHC class II transactivator CIITA

    Article • Frontiers in Immunology, March 2023, Frontiers

    MD, PhD Roberto S Accolla

  7. Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine

    Article • EBioMedicine, February 2023, Elsevier

    MD, PhD Roberto S Accolla

  8. The endogenous HBZ interactome in ATL leukemic cells reveals an unprecedented complexity of host interacting partners involved in RNA splicing

    Article • Frontiers in Immunology, August 2022, Frontiers

    MD, PhD Roberto S Accolla

  9. The Road to HTLV-1-Induced Leukemia by Following the Subcellular Localization of HTLV-1-Encoded HBZ Protein

    Article • Frontiers in Immunology, June 2022, Frontiers

    MD, PhD Roberto S Accolla

  10. Reply to the Letter to the Editor: “Importance of nasal secretions in the evaluation of mucosal immunity elicited by mRNA BNT162b2 COVID-19 vaccine” by Francavilla B et al.

    Article • EBioMedicine, May 2022, Elsevier

    MD, PhD Roberto S Accolla

  11. Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma

    Article • Clinical Cancer Research, April 2022, American Association for Cancer Research (AACR)

    MD, PhD Roberto S Accolla

  12. Mucosal immune response in BNT162b2 COVID-19 vaccine recipients

    Article • EBioMedicine, January 2022, Elsevier

    MD, PhD Roberto S Accolla

  13. HTLV-1 Infection and Pathogenesis: New Insights from Cellular and Animal Models

    Article • International Journal of Molecular Sciences, July 2021, MDPI AG

    MD, PhD Roberto S Accolla

  14. Dual cytoplasmic and nuclear localization of HTLV-1-encoded HBZ protein is a unique feature of adult T-cell leukemia

    Article • Haematologica, February 2021, Ferrata Storti Foundation (Haematologica)

    MD, PhD Roberto S Accolla

  15. HTLV-1 Infection and Adult T Cell Leukemia Mechanisms of Oncogenesis and Alteration of Immunity

    Article • January 2021, Vide Leaf

    MD, PhD Roberto S Accolla

  16. CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens

    Article • Molecular & Cellular Proteomics, January 2021, Elsevier

    MD, PhD Roberto S Accolla

  17. Epigenetic silencing of HTLV-1 expression by the HBZ RNA through interference with the basal transcription machinery

    Article • Blood Advances, November 2020, American Society of Hematology

    MD, PhD Roberto S Accolla

  18. Unveiling the Hidden Treasury: CIITA-Driven MHC Class II Expression in Tumor Cells to Dig up the Relevant Repertoire of Tumor Antigens for Optimal Stimulation of Tumor Specific CD4+ T Helper Cells

    Article • Cancers, October 2020, MDPI AG

    MD, PhD Roberto S Accolla

  19. Editorial: Novel Strategies for Anti-Tumor Vaccines

    Article • Frontiers in Immunology, January 2020, Frontiers

    MD, PhD Roberto S Accolla

  20. Novel Strategies of Anti-Tumor Vaccines

    Article • January 2020, Frontiers

    MD, PhD Roberto S Accolla

  21. Restriction factors in human retrovirus infections and the unprecedented case of CIITA as link of intrinsic and adaptive immunity against HTLV-1

    Article • Retrovirology, November 2019, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  22. Interferon-inducible TRIM22 contributes to maintenance of HIV-1 proviral latency in T cell lines

    Article • Virus Research, August 2019, Elsevier

    Fabio Saliu, MD, PhD Roberto S Accolla

  23. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine

    Article • Frontiers in Immunology, July 2019, Frontiers

    MD, PhD Roberto S Accolla

  24. HTLV-1 HBZ Protein Resides Exclusively in the Cytoplasm of Infected Cells in Asymptomatic Carriers and HAM/TSP Patients

    Article • Frontiers in Microbiology, April 2019, Frontiers

    MD, PhD Roberto S Accolla

  25. A-104 Tracing the intracellular journey of HTLV-1 HBZ during infection: From asymptomatic carriers to HAM/TSP ending to ATL: A one-way ticket?

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, April 2019, Wolters Kluwer Health

    MD, PhD Roberto S Accolla

  26. CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches

    Article • OncoImmunology, November 2018, Taylor & Francis

    MD, PhD Roberto S Accolla

  27. B-104 Cancer vaccine: Tumor immunology meets...Immunology

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, April 2018, Wolters Kluwer Health

    MD, PhD Roberto S Accolla

  28. D-105 Reversible HIV-1 Latency Induced in Primary Human Monocyte-Derived Macrophages by Repeated M1 Polarization

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, April 2018, Wolters Kluwer Health

    MD, PhD Roberto S Accolla

  29. Neonatal Fc receptor is involved in the protection of fibrinogen after its intake in peripheral blood mononuclear cells

    Article • Journal of Translational Medicine, March 2018, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  30. HTLV-1 HBZ Viral Protein: A Key Player in HTLV-1 Mediated Diseases

    Article • Frontiers in Microbiology, December 2017, Frontiers

    MD, PhD Roberto S Accolla

  31. Tripartite Motif 22 and Class II Transactivator Restriction Factors: Unveiling Their Concerted Action against Retroviruses

    Article • Frontiers in Immunology, October 2017, Frontiers

    MD, PhD Roberto S Accolla

  32. New concept in Immunology

    Article • OncoImmunology, July 2017, Taylor & Francis

    MD, PhD Roberto S Accolla

  33. P-C22 The constitutive activation of NF-kB by HTLV-1 Tax-1 oncoprotein is inhibited by the MHC class II transactivator CIITA

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, March 2017, Wolters Kluwer Health

    MD, PhD Roberto S Accolla

  34. P-C4 The MHC class II transactivator CIITA acts as a restriction factor for HIV in human myeloid cells

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, March 2017, Wolters Kluwer Health

    MD, PhD Roberto S Accolla

  35. Abstract A014: CIITA dependent MHC class II IA expression in tumor cells triggers CD4 T cell protective and long lasting antitumor immunity

    Article • Cancer Immunology Research, October 2016, American Association for Cancer Research (AACR)

    MD, PhD Roberto S Accolla

  36. The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells

    Article • Journal of Translational Medicine, April 2016, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  37. The Major Histocompatibility Complex Class II Transactivator CIITA Inhibits the Persistent Activation of NF-κB by the Human T Cell Lymphotropic Virus Type 1 Tax-1 Oncoprotein

    Article • Journal of Virology, January 2016, ASM Journals

    MD, PhD Roberto S Accolla

  38. Abstract B047: Adequate Antigen Availability (AAA) in antitumor immunity: Definition and consequences for novel strategies of tumor prevention and antitumor treatment

    Article • Cancer Immunology Research, January 2016, American Association for Cancer Research (AACR)

    MD, PhD Roberto S Accolla

  39. Abstract B048: The MHC class II transactivator CIITA inhibits the persistent activation of NF-kB by Human T cell Lymphotropic Virus type-1 Tax-1 oncoprotein

    Article • Cancer Immunology Research, January 2016, American Association for Cancer Research (AACR)

    MD, PhD Roberto S Accolla

  40. The MHC Class II transactivator CIITA inhibits the persistent activation of NF-kB by Tax-1

    Article • Retrovirology, August 2015, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  41. Localization, quantization and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL

    Article • Retrovirology, August 2015, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  42. Localization, quantization and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL

    Article • Retrovirology, August 2015, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  43. Localization, quantification and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL

    Article • Retrovirology, July 2015, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  44. Class II Transactivator-Induced MHC Class II Expression in Pancreatic Cancer Cells Leads to Tumor Rejection and a Specific Antitumor Memory Response

    Article • Pancreas, October 2014, Wolters Kluwer Health

    MD, PhD Roberto S Accolla

  45. Boosting the MHC Class II-Restricted Tumor Antigen Presentation to CD4+ T Helper Cells: A Critical Issue for Triggering Protective Immunity and Re-Orienting the Tumor Microenvironment Toward an Anti-Tumor State

    Article • Frontiers in Oncology, January 2014, Frontiers

    MD, PhD Roberto S Accolla

  46. Investigating Human T Cell Lymphotropic Retrovirus (HTLV) Tax Function with Molecular and Immunophenotypic Techniques

    Article • January 2014, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  47. The MHC Class II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation

    Article • Retrovirology, January 2014, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  48. P105 The MHC-II transactivator CIITA is a viral restriction factor against HIV-1 replication

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, April 2013, Wolters Kluwer Health

    MD, PhD Roberto S Accolla

  49. P104 Suitable Antigen Availability

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, April 2013, Wolters Kluwer Health

    MD, PhD Roberto S Accolla

  50. P101 The MHC-II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kBactivation

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, April 2013, Wolters Kluwer Health

    MD, PhD Roberto S Accolla

  51. The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators

    Article • Frontiers in Microbiology, January 2013, Frontiers

    MD, PhD Roberto S Accolla

  52. Adequate Antigen Availability: A Key Issue for Novel Approaches to Tumor Vaccination and Tumor Immunotherapy

    Article • Journal of Neuroimmune Pharmacology, December 2012, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  53. Down syndrome, autoimmunity and T regulatory cells

    Article • Clinical & Experimental Immunology, August 2012, Oxford University Press (OUP)

    MD, PhD Roberto S Accolla

  54. Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines

    Article • Journal of Translational Medicine, July 2012, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  55. Typing of a Polymorphic Human Gene Conferring Susceptibility to Insulin-Dependent Diabetes Mellitus by Picosecond-Resolved FRET on Non-Purified/Non-Amplified Genomic DNA

    Article • DNA Research, June 2012, Oxford University Press (OUP)

    MD, PhD Roberto S Accolla

  56. Dendritic Cell Editing by Activated Natural Killer Cells Results in a More Protective Cancer-Specific Immune Response

    Article • PLoS ONE, June 2012, PLOS

    Dr Laura Chiossone, MD, PhD Roberto S Accolla

  57. Picosecond-resolved FRET on non-amplified DNA for identifying individuals genetically susceptible to type-1 diabetes

    Article • May 2012, SPIE

    MD, PhD Roberto S Accolla

  58. E1 Molecular and Cellular Correlates of the CIITA-Mediated Inhibition of HTLV-2 Tax-2 Transactivator Function Resulting in Loss of Viral Replication

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, April 2012, Wolters Kluwer Health

    MD, PhD Roberto S Accolla

  59. Major Histocompatibility Complex Class II Transactivator CIITA Is a Viral Restriction Factor That Targets Human T-Cell Lymphotropic Virus Type 1 Tax-1 Function and Inhibits Viral Replication

    Article • Journal of Virology, August 2011, ASM Journals

    MD, PhD Roberto S Accolla

  60. Molecular and cellular correlates of the CIITA-mediated inhibition of HTLV-2 Tax-2 transactivator function resulting in loss of viral replication

    Article • Journal of Translational Medicine, July 2011, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  61. MHC class II transactivator CIITA inhibits Tax-2-mediated HTLV-2 LTR transactivation and viral replication by binding to, and affecting Tax-2 intracellular localization

    Article • Retrovirology, June 2011, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  62. The MHC-II transactivator CIITA, a viral restriction factor inhibiting the replication of Human T-Cell Lymphotropic Virus Type 1

    Article • Retrovirology, June 2011, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  63. 202 The MHC Class II Transactivator CIITA, a Restriction Factor for Human Retroviruses and a Molecule Making the Bridge Between Adaptive and Intrinsic Immunity

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, April 2011, Wolters Kluwer Health

    MD, PhD Roberto S Accolla

  64. 231 The MHC Class II Transactivator, CIITA, is a Viral Restriction Factor for Human Oncogenic Retroviruses

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, April 2011, Wolters Kluwer Health

    MD, PhD Roberto S Accolla

  65. New Strategies of Mammary Cancer Vaccination

    Article • The Breast Journal, September 2010, Hindawi Publishing Corporation

    MD, PhD Roberto S Accolla

  66. CIITA‐driven MHC‐II positive tumor cells: Preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy

    Article • International Journal of Cancer, August 2010, Wiley

    MD, PhD Roberto S Accolla

  67. Therapy‐induced antitumor vaccination in neuroblastomas by the combined targeting of IL‐2 and TNFα

    Article • International Journal of Cancer, April 2010, Wiley

    MD, PhD Roberto S Accolla

  68. 153 Insight into the molecular mechanism of CIITA-mediated inhibition of HIV-1 and HTLV transactivators

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, June 2009, Wolters Kluwer Health

    MD, PhD Roberto S Accolla

  69. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions

    Article • International Immunology, April 2009, Oxford University Press (OUP)

    MD, PhD Roberto S Accolla

  70. NK cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs

    Article • International Immunology, March 2009, Oxford University Press (OUP)

    MD, PhD Roberto S Accolla

  71. Unsung Hero Robert C. Gallo

    Article • Science, January 2009, American Association for the Advancement of Science

    Dr Maria Lina Tornesello , Donato Zipeto, MD, PhD Roberto S Accolla

  72. The dual function of the MHC class II transactivator CIITA against HTLV retroviruses

    Article • Frontiers in Bioscience-Landmark, January 2009, IMR Press

    MD, PhD Roberto S Accolla

  73. Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-  in promyelocytic cells

    Article • International Immunology, September 2008, Oxford University Press (OUP)

    MD, PhD Roberto S Accolla

  74. Experimental therapeutic approaches to adenocarcinoma: The potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer

    Article • Surgical Oncology, December 2007, Elsevier

    MD, PhD Roberto S Accolla

  75. Therapy-induced antitumor vaccination by targeting tumor necrosis factor-α to tumor vessels in combination with melphalan

    Article • European Journal of Immunology, December 2007, Wiley

    MD, PhD Roberto S Accolla

  76. A dual defensive role of CIITA against retroviral infections

    Article • Retrovirology, December 2006, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  77. Inhibition of human T cell leukemia virus type 2 replication by the suppressive action of class II transactivator and nuclear factor Y

    Article • Proceedings of the National Academy of Sciences, August 2006, Proceedings of the National Academy of Sciences

    MD, PhD Roberto S Accolla

  78. Host Defense Mechanisms against Pathogens

    Article • Surgical Infections, July 2006, Mary Ann Liebert Inc

    MD, PhD Roberto S Accolla

  79. CIITA-Induced MHC Class II Expression in Mammary Adenocarcinoma Leads to a Th1 Polarization of the Tumor Microenvironment, Tumor Rejection, and Specific Antitumor Memory

    Article • Clinical Cancer Research, June 2006, American Association for Cancer Research (AACR)

    MD, PhD Roberto S Accolla

  80. Targeted Delivery of Tumor Necrosis Factor-α to Tumor Vessels Induces a Therapeutic T Cell–Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic Origin

    Article • Clinical Cancer Research, April 2006, American Association for Cancer Research (AACR)

    MD, PhD Roberto S Accolla

  81. The MHC Class II Transactivator (CIITA): A "Physiologic" Drug Against HIV-1 Replication

    Article • Retrovirology, December 2005, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  82. 7he MHC Class II Transactivator (CIITA): A Physiologic Inhibitor of HTLV-2 Retroviral Infection

    Article • Retrovirology, December 2005, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  83. The Molecular and Cellular Basis of Tumor Rejection After Vaccination With Mammary Adenocarcinoma Cells Transduced With the MHC Class II Transactivator CIITA

    Article • Retrovirology, December 2005, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  84. Human Naive CD4 T-Cell Clones Specific for HIV Envelope Persist for Years In Vivo in the Absence of Antigenic Challenge

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, October 2005, Wolters Kluwer Health

    MD, PhD Roberto S Accolla

  85. MHC immunoevasins: protecting the pathogen reservoir in infection

    Article • Tissue Antigens, June 2005, Wiley

    MD, PhD Roberto S Accolla

  86. The MHC class?II transactivator (CIITA) mRNA stability is critical for the HLA class?II gene expression in myelomonocytic cells

    Article • European Journal of Immunology, February 2005, Wiley

    MD, PhD Roberto S Accolla

  87. Sequential Immunogene Therapy with Interleukin-12– and Interleukin-15–Engineered Neuroblastoma Cells Cures Metastatic Disease in Syngeneic Mice

    Article • Clinical Cancer Research, January 2005, American Association for Cancer Research (AACR)

    MD, PhD Roberto S Accolla

  88. Article • BMC Microbiology, January 2005, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  89. Re: Lack of Serologic Evidence for Prevalent Simian Virus 40 Infection in Humans

    Article • JNCI Journal of the National Cancer Institute, May 2004, Oxford University Press (OUP)

    MD, PhD Roberto S Accolla

  90. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28− T cells and inhibit both T-Cell proliferation and CTL function

    Article • Human Immunology, February 2004, Elsevier

    MD, PhD Roberto S Accolla

  91. The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2

    Article • Blood, February 2004, American Society of Hematology

    MD, PhD Roberto S Accolla

  92. Different levels of control prevent interferon-γ-inducible HLA-class II expression in human neuroblastoma cells

    Article • Oncogene, October 2003, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  93. Identification of Immunodominant Epitopes in Inactivated Tat-Vaccinated Healthy and HIV-1–Infected Volunteers

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, May 2003, Wolters Kluwer Health

    MD, PhD Roberto S Accolla

  94. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells

    Article • European Journal of Immunology, April 2003, Wiley

    MD, PhD Roberto S Accolla

  95. The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication

    Article • European Journal of Immunology, October 2002, Wiley

    MD, PhD Roberto S Accolla

  96. Block of Stat-1 activation in macrophages phagocytosing bacteria causes reduced transcription of CIITA and consequent impaired antigen presentation

    Article • European Journal of Immunology, May 2002, Wiley

    MD, PhD Roberto S Accolla

  97. Preservation of clonal heterogeneity of the Pneumocystis carinii -specific CD4 T cell repertoire in HIV infected, asymptomatic individuals

    Article • Clinical & Experimental Immunology, April 2002, Wiley

    Dr Emanuele Pontali, MD, PhD Roberto S Accolla

  98. Analysis of the antigen specific T cell repertoires in HIV infection

    Article • Immunology Letters, November 2001, Elsevier

    Professor Arianna Loregian, Dr Emanuele Pontali, MD, PhD Roberto S Accolla

  99. The MHC class II transactivator: prey and hunter in infectious diseases

    Article • Trends in Immunology, October 2001, Elsevier

    MD, PhD Roberto S Accolla

  100. The AIR-1 encoded class II transactivator (CIITA): the master coordinator of MHC class II gene expression and ..more

    Article • January 2001, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  101. Tat Protein Is an HIV-1-Encoded β-Chemokine Homolog That Promotes Migration and Up-Regulates CCR3 Expression on Human FcεRI+ Cells

    Article • The Journal of Immunology, December 2000, The American Association of Immunologists

    MD, PhD Roberto S Accolla

  102. ChemInform Abstract: HLA and Cancer: 12th International Histocompatibility Workshop Study

    Article • ChemInform, July 2000, Wiley

    MD, PhD Roberto S Accolla

  103. Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR

    Article • European Journal of Immunology, April 2000, Wiley

    MD, PhD Roberto S Accolla

  104. HIV-1 Tat mutants in the cysteine-rich region downregulate HLA class II expression in T lymphocytic and macrophage cell lines

    Article • European Journal of Immunology, January 2000, Wiley

    MD, PhD Roberto S Accolla

  105. HIV-1 Tat mutants in the cysteine-rich region downregulate HLA class II expression in T lymphocytic and macrophage cell lines

    Article • European Journal of Immunology, January 2000, Wiley

    MD, PhD Roberto S Accolla

  106. MHC class II gene regulation: some historical considerations on a still ontogenetic and phylogenetic puzzle

    Article • Microbes and Infection, September 1999, Elsevier

    MD, PhD Roberto S Accolla

  107. MHC class II gene regulation: some historical considerations on a still ontogenetic and phylogenetic puzzle

    Article • Microbes and Infection, September 1999, Elsevier

    MD, PhD Roberto S Accolla

  108. Distinct regulation of HLA class II and class I cell surface expression in the THP-1 macrophage cell line after bacterial phagocytosis

    Article • European Journal of Immunology, February 1999, Wiley

    MD, PhD Roberto S Accolla

  109. HLA-DQ Genotype in Early Onset Insulin Dependent Diabetes Mellitus

    Article • Journal of Pediatric Endocrinology and Metabolism, January 1999, De Gruyter

    MD, PhD Roberto S Accolla

  110. Double-stranded deoxyribonucleic acid binds to HLA class II molecules and inhibits HLA class II-mediated antigen presentation

    Article • European Journal of Immunology, December 1998, Wiley

    MD, PhD Roberto S Accolla

  111. Double-stranded deoxyribonucleic acid binds to HLA class II molecules and inhibits HLA class II-mediated antigen presentation

    Article • European Journal of Immunology, December 1998, Wiley

    MD, PhD Roberto S Accolla

  112. Human T-Cell Leukemia Virus Type II Directly Acts on CD34+ Hematopoietic Precursors by Increasing Their Survival Potential. Envelope-Associated HLA Class II Molecules Reverse This Effect

    Article • Blood, April 1998, American Society of Hematology

    MD, PhD Roberto S Accolla

  113. Human T-Cell Leukemia Virus Type II Directly Acts on CD34+ Hematopoietic Precursors by Increasing Their Survival Potential. Envelope-Associated HLA Class II Molecules Reverse This Effect

    Article • Blood, April 1998, American Society of Hematology

    MD, PhD Roberto S Accolla

  114. HLA and MHC: Genes Molecules and function

    Article • Immunology Today, April 1997, Elsevier

    MD, PhD Roberto S Accolla

  115. A Girl with Diabetes and Severe Combined Immunodeficiency from Adenosine Deaminase Deficiency

    Article • Journal of Pediatric Endocrinology and Metabolism, January 1997, De Gruyter

    MD, PhD Roberto S Accolla

  116. Functional significance of polymorphism among MHC class II gene promoters

    Article • Tissue Antigens, December 1996, Wiley

    MD, PhD Roberto S Accolla

  117. APC gene mutations and allelic losses in sporadic ampullary tumours: Evidence of genetic difference from tumours associated with familial adenomatous polyposis

    Article • International Journal of Cancer, November 1996, Wiley

    MD, PhD Roberto S Accolla

  118. Active suppression of the class II transactivator-encodingAIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells

    Article • European Journal of Immunology, October 1996, Wiley

    MD, PhD Roberto S Accolla

  119. Expression of MHC class I and class II antigens in pancreatic adenocarcinomas

    Article • Tissue Antigens, October 1996, Wiley

    MD, PhD Roberto S Accolla

  120. Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells.

    Article • The Journal of Immunology, June 1996, The American Association of Immunologists

    MD, PhD Roberto S Accolla

  121. Induction of CIITA and modifications of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-γ

    Article • Human Immunology, April 1996, Elsevier

    MD, PhD Roberto S Accolla

  122. Divergent evolution in the mechanisms controlling major histocompatibility complex class II gene transcription in mouse and human

    Article • European Journal of Immunology, January 1996, Wiley

    MD, PhD Roberto S Accolla

  123. Transcriptional regulation of MHC class II genes

    Article • International Journal of Clinical & Laboratory Research, June 1995, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  124. MHC: orchestrating the immune response

    Article • Immunology Today, January 1995, Elsevier

    MD, PhD Roberto S Accolla

  125. Interspecies somatic T cell hybrids as biological tools for studying gene expression during T cell development

    Article • International Journal of Clinical & Laboratory Research, December 1994, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  126. Evidence for a specific post-transcriptional mechanism controlling the expression of HLA-DQ, but not -DR and -DP, molecules.

    Article • The Journal of Immunology, November 1994, The American Association of Immunologists

    MD, PhD Roberto S Accolla

  127. In vivo modification of major histocompatibility complex class II DRA promoter occupancy mediated by the AIR‐1 trans‐activator

    Article • European Journal of Immunology, October 1994, Wiley

    MD, PhD Roberto S Accolla

  128. ras-family gene mutations in neoplasia of the ampulla of vater

    Article • International Journal of Cancer, October 1994, Wiley

    MD, PhD Roberto S Accolla

  129. Assessment of the DQB1-DQA1 Complete Genotype Allows Best Prediction for IDDM

    Article • Diabetes Care, September 1994, American Diabetes Association

    MD, PhD Roberto S Accolla

  130. Evidence for a trans-acting activator function regulating the expression of the human CD5 antigen

    Article • Immunogenetics, July 1994, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  131. Pancreatic cancer in europe: Ki‐ras gene mutation pattern shows geographical differences

    Article • International Journal of Cancer, April 1994, Wiley

    MD, PhD Roberto S Accolla

  132. The complex interplay of the DQB1 and DQA1 loci in the generation of the susceptible and protective phenotype for insulin-dependent diabetes mellitus

    Article • Molecular Immunology, April 1994, Elsevier

    MD, PhD Roberto S Accolla

  133. Physiologic target of the Air-1 trans-activator revealed by stable transfection assay

    Article • Immunogenetics, January 1994, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  134. Role of the HLA-DQ Genotype in IDDM Susceptibility

    Article • January 1994, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  135. Susceptibility of Human–Mouse T Cell Hybrids to HIV-Productive Infection

    Article • AIDS Research and Human Retroviruses, December 1993, Mary Ann Liebert Inc

    MD, PhD Roberto S Accolla

  136. Detection of human chromosomes in somatic cell hybrids by PCR analysis

    Article • Cytogenetic and Genome Research, January 1993, Karger Publishers

    MD, PhD Roberto S Accolla

  137. HLA-DQB1 typing of north east Italian IDDM patients using amplified DNA, oligonucleotide probes and a rapid DNA-enzyme immunoassay (DEIA)

    Article • Molecular Immunology, January 1993, Elsevier

    MD, PhD Roberto S Accolla

  138. Constitutive expression of CD69 in interspecies T-cell hybrids and locus assignment to human chromosome 12

    Article • Immunogenetics, June 1992, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  139. Staphylococcal enterotoxin-dependent lysis of MHC class II negative target cells by cytolytic T lymphocytes.

    Article • The Journal of Immunology, April 1991, The American Association of Immunologists

    MD, PhD Roberto S Accolla

  140. The molecular biology of MHC genes

    Article • Immunology Today, April 1991, Elsevier

    MD, PhD Roberto S Accolla

  141. Structural analysis of the CD69 early activation antigen by two monoclonal antibodies directed to different epitopes

    Article • Molecular Immunology, January 1991, Elsevier

    MD, PhD Roberto S Accolla

  142. CELL lineage-specific and developmental stage-specific controls of MHC class-II-antigen expression

    Article • International Journal of Cancer, January 1991, Wiley

    MD, PhD Roberto S Accolla

  143. Inducible and constitutive MHC class II gene expression. Distinct tissue-specific genetic controls.

    Article • The Journal of Immunology, September 1990, The American Association of Immunologists

    MD, PhD Roberto S Accolla

  144. Loss of a DNA-protein complex correlates with extinguished major histocompatibility complex class II expression in a human B cell.

    Article • The Journal of Experimental Medicine, June 1990, Rockefeller University Press

    MD, PhD Roberto S Accolla

  145. Superinfection by Epstein-Barr virus of a subset of Raji cells is independent of HLA class-II antigens

    Article • International Journal of Cancer, May 1990, Wiley

    MD, PhD Roberto S Accolla

  146. A family of trans-acting factors with distinct regulatory functions control expression of MHC class II genes

    Article • Immunologic Research, March 1990, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  147. Different staphylococcal enterotoxins bind preferentially to distinct major histocompatibility complex class ii isotypes

    Article • European Journal of Immunology, November 1989, Wiley

    MD, PhD Roberto S Accolla

  148. Transcriptional control of MHC class II gene expression during differentiation from B cells to plasma cells.

    Article • The Journal of Immunology, April 1989, The American Association of Immunologists

    MD, PhD Roberto S Accolla

  149. Activated Ras Oncogenes Partially Complement the Transcriptional Defects in Class II-Negative Mutant B-Cell Lines

    Article • January 1989, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  150. Effects of recombinant human tumor necrosis factor‐α on the surface phenotype and the growth of human malignant glioma cell lines

    Article • International Journal of Cancer, November 1988, Wiley

    MD, PhD Roberto S Accolla

  151. Heterogeneity of lymphokyne-activated killer (LAK) populations at the clonal level: Both NK and CD3+, CD4−, CD8− clones efficiently mediate tumor cell killing

    Article • Clinical Immunology and Immunopathology, October 1988, Elsevier

    MD, PhD Roberto S Accolla

  152. Two distinct genetic loci regulating class II gene expression are defective in human mutant and patient cell lines.

    Article • The EMBO Journal, July 1988, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  153. An enhancer factor defect in a mutant Burkitt lymphoma cell line.

    Article • The Journal of Experimental Medicine, June 1988, Rockefeller University Press

    MD, PhD Roberto S Accolla

  154. Active suppression of major histocompatibility complex class II gene expression during differentiation from B cells to plasma cells.

    Article • Proceedings of the National Academy of Sciences, April 1988, Proceedings of the National Academy of Sciences

    MD, PhD Roberto S Accolla

  155. Molecular genotyping of the HLA-DQ ? gene region

    Article • Immunogenetics, January 1988, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  156. Defective HLA class II expression in a regulatory mutant is partially complemented by activated ras oncogenes.

    Article • Proceedings of the National Academy of Sciences, December 1987, Proceedings of the National Academy of Sciences

    MD, PhD Roberto S Accolla

  157. Expression of HLA-DR antigen in human class II mutant B-cell lines by double infection with retrovirus vectors.

    Article • Molecular and Cellular Biology, November 1987, ASM Journals

    MD, PhD Roberto S Accolla

  158. Expression of HLA-DR Antigen in Human Class II Mutant B-Cell Lines by Double Infection with Retrovirus Vectors

    Article • Molecular and Cellular Biology, November 1987, Taylor & Francis

    MD, PhD Roberto S Accolla

  159. Distinct mechanisms regulate MHC class II gene expression in B cells and macrophages.

    Article • The Journal of Immunology, August 1987, The American Association of Immunologists

    MD, PhD Roberto S Accolla

  160. Structural analysis of human Ia antigens reveals the existence of a fourth molecular subset distinct from DP, DQ, and DR molecules.

    Article • The Journal of Experimental Medicine, January 1987, Rockefeller University Press

    MD, PhD Roberto S Accolla

  161. Stable integration of mouse DNA into Ia-negative human B-lymphoma cells causes reexpression of the human Ia-positive phenotype.

    Article • Proceedings of the National Academy of Sciences, October 1986, Proceedings of the National Academy of Sciences

    MD, PhD Roberto S Accolla

  162. aIr-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression.

    Article • The Journal of Experimental Medicine, July 1986, Rockefeller University Press

    MD, PhD Roberto S Accolla

  163. H2-restricted recognition of cloned HLA class I gene products expressed in mouse cells.

    Article • The Journal of Immunology, June 1986, The American Association of Immunologists

    MD, PhD Roberto S Accolla

  164. The genes for lumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta) are tandemly arranged on chromosome 17 of the mouse

    Article • Nucleic Acids Research, January 1986, Oxford University Press (OUP)

    MD, PhD Roberto S Accolla

  165. Expression of Class II Antigens on Nonhematopoietic Tumor Cells

    Article • January 1986, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  166. Trans-acting element(s) operating across species barriers positively regulate expression of major histocompatibility complex class II genes.

    Article • The Journal of Experimental Medicine, October 1985, Rockefeller University Press

    MD, PhD Roberto S Accolla

  167. Reactivation by a trans-acting factor of human major histocompatibility complex Ia gene expression in interspecies hybrids between an Ia-negative human B-cell variant and an Ia-positive mouse B-cell lymphoma.

    Article • Proceedings of the National Academy of Sciences, August 1985, Proceedings of the National Academy of Sciences

    MD, PhD Roberto S Accolla

  168. The human Ia-associated invariant chain is synthesized in Ia-negative B cell variants and is not expressed on the cell surface of both Ia-negative and Ia-positive parental cells.

    Article • The Journal of Immunology, May 1985, The American Association of Immunologists

    MD, PhD Roberto S Accolla

  169. Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells

    Article • Nature, December 1984, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  170. Analysis of the structural heterogeneity and polymorphism of human Ia antigens. Four distinct subsets of molecules are coexpressed in the Ia pool of both DR1,1 homozygous and DR3,W6 heterozygous B cell lines.

    Article • The Journal of Experimental Medicine, February 1984, Rockefeller University Press

    MD, PhD Roberto S Accolla

  171. Ia-negative B-cell variants reveal a coordinate regulation in the transcription of the HLA Class II gene family

    Article • Immunogenetics, January 1984, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  172. Biochemical aspects of human Ia molecules

    Article • Human Immunology, September 1983, Elsevier

    MD, PhD Roberto S Accolla

  173. Isolation of cDNA clones for the p33 invariant chain associated with HLA-DR antigens.

    Article • Proceedings of the National Academy of Sciences, September 1983, Proceedings of the National Academy of Sciences

    MD, PhD Roberto S Accolla

  174. The importance of cross-reactions between species: Mouse allo-anti-Ia monoclonal antibodies as a powerful tool to define human Ia subsets

    Article • Human Immunology, September 1983, Elsevier

    MD, PhD Roberto S Accolla

  175. Human B cell variants immunoselected against a single Ia antigen subset have lost expression of several Ia antigen subsets.

    Article • The Journal of Experimental Medicine, March 1983, Rockefeller University Press

    MD, PhD Roberto S Accolla

  176. A Monoclonal Antibody Directed Against HLA-DR Molecules Inhibits the Interleukin-2-Dependent T Cell Proliferation in Humans

    Article • January 1983, Elsevier

    MD, PhD Roberto S Accolla

  177. Distinct HLA‐DR epitopes and distinct families of HLA‐DR molecules defined by 15 monoclonal antibodies (mAb) either anti‐DR or allo‐anti‐Iak crossreacting with human DR molecule. I. Cross‐inhibition studies of mAb cell surface fixation and d...

    Article • European Journal of Immunology, January 1983, Wiley

    MD, PhD Roberto S Accolla

  178. Antibody-Mediated Activation of Genetically Defective Escherichia Coli Galactosidases by Monoclonal Antibodies

    Article • January 1983, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  179. Structural heterogeneity of the human Ia molecular pool as detected by cross-reacting mouse monoclonal antibodies.

    Article • The Journal of Immunology, January 1983, The American Association of Immunologists

    MD, PhD Roberto S Accolla

  180. Isolation of distinct cDNA clones encoding HLA-DR beta chains by use of an expression assay.

    Article • Proceedings of the National Academy of Sciences, December 1982, Proceedings of the National Academy of Sciences

    MD, PhD Roberto S Accolla

  181. Isolation of cDNA clones encoding HLA-DR alpha chains.

    Article • Proceedings of the National Academy of Sciences, November 1982, Proceedings of the National Academy of Sciences

    MD, PhD Roberto S Accolla

  182. Sandwich enzyme immunoassay using three monoclonal antibodies against different epitopes of carcinoembryonic antigen (CEA)

    Article • Immunology Letters, August 1982, Elsevier

    MD, PhD Roberto S Accolla

  183. Translation and assembly of HLA-DR antigens in Xenopus oocytes injected with mRNA from a human B-cell line.

    Article • The EMBO Journal, May 1982, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  184. Monoclonal antibodies against carcinoembryonic antigen (CEA) used in a solid-phase enzyme immunoassay. First clinical results

    Article • Journal of Immunological Methods, March 1982, Elsevier

    MD, PhD Roberto S Accolla

  185. IL-2-mediated T cell proliferation in humans is blocked by a monoclonal antibody directed against monomorphic determinants of HLA-DR antigens.

    Article • The Journal of Experimental Medicine, February 1982, Rockefeller University Press

    MD, PhD Roberto S Accolla

  186. Functional Analysis of Human Ia Subsets

    Article • January 1982, Elsevier

    MD, PhD Roberto S Accolla

  187. Biochemical Analysis of Human HLA-DR Molecules

    Article • January 1982, Elsevier

    MD, PhD Roberto S Accolla

  188. Monoclonal Antibodies as a Tool to Detect Melanoma-Associated Antigens

    Article • January 1982, Springer Science + Business Media

    MD, PhD Roberto S Accolla

  189. Demonstration at the single‐cell level of the existence of distinct clusters of epitopes in two predefined human Ia molecular subsets

    Article • European Journal of Immunology, January 1982, Wiley

    MD, PhD Roberto S Accolla

  190. Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy

    Article • Immunology Today, December 1981, Elsevier

    MD, PhD Roberto S Accolla

  191. Allogeneic mixed lymphocyte reactions in humans: pretreatment of either the stimulator or the responder cell population with monoclonal anti-Ia antibodies leads to an inhibition of cell proliferation.

    Article • The Journal of Immunology, December 1981, The American Association of Immunologists

    MD, PhD Roberto S Accolla

  192. Distinct forms of both alpha and beta subunits are present in the human Ia molecular pool.

    Article • Proceedings of the National Academy of Sciences, July 1981, Proceedings of the National Academy of Sciences

    MD, PhD Roberto S Accolla

  193. Subsets of human Ia-like molecules defined by monoclonal antibodies

    Article • Molecular Immunology, May 1981, Elsevier

    MD, PhD Roberto S Accolla

  194. Antibody-mediated activation of genetically defective Escherichia coli beta-galactosidases by monoclonal antibodies produced by somatic cell hybrids.

    Article • Proceedings of the National Academy of Sciences, April 1981, Proceedings of the National Academy of Sciences

    MD, PhD Roberto S Accolla

  195. Binding of one monoclonal antibody to human Ia molecules can be enhanced by a second monoclonal antibody

    Article • European Journal of Immunology, January 1981, Wiley

    Professor Rosa Sorrentino, MD, PhD Roberto S Accolla

  196. Somatic cell hybrids producing antibodies specific to human fibronectin

    Article • International Journal of Cancer, March 1980, Wiley

    MD, PhD Roberto S Accolla

  197. Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines.

    Article • Proceedings of the National Academy of Sciences, January 1980, Proceedings of the National Academy of Sciences

    MD, PhD Roberto S Accolla

  198. Immune response against the β‐galactosidase enzyme of E. Coli at precursor cell level. I. Analysis of the secondary repertoire in BALB/c mice

    Article • European Journal of Immunology, October 1978, Wiley

    MD, PhD Roberto S Accolla

  199. Idiotype‐specific neonatal suppression of phosphorylcholine‐responsive B cells

    Article • European Journal of Immunology, December 1977, Wiley

    MD, PhD Roberto S Accolla

  200. Antibody‐mediated activation of a deletion‐mutant β‐galactosidase defective in the α region

    Article • FEBS Letters, September 1976, Wiley

    MD, PhD Roberto S Accolla